TScan Therapeutics, Inc.
General ticker "TCRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $157.6M (TTM average)
TScan Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -19.8%.
Estimated limits based on current volatility of 5.9%: low 0.21$, high 0.24$
Factors to consider:
- Total employees count: 142 (-27.2%) as of 2025
- Top business risk factors: Operating losses, Clinical trial failure, Regulatory and compliance, Liquidity and credit risks, Manufacturing issues
- Current price 63.0% below estimated low
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.62$, 1.99$]
- 2026-12-31 to 2027-12-31 estimated range: [0.74$, 2.19$]
Financial Metrics affecting the TCRX estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 84.56 > 2.08
- Negative: negative Operating cash flow
- Positive: 49.86 < Shareholder equity ratio, % of 53.82 <= 58.56
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
Short-term TCRX quotes
Long-term TCRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $21.05MM | $2.82MM | $10.32MM |
| Operating Expenses | $114.51MM | $137.64MM | $146.14MM |
| Operating Income | $-93.46MM | $-134.82MM | $-135.81MM |
| Non-Operating Income | $4.24MM | $7.32MM | $6.05MM |
| Interest Expense | $3.76MM | $3.65MM | $2.77MM |
| R&D Expense | $88.15MM | $107.35MM | $114.15MM |
| Income(Loss) | $-89.22MM | $-127.50MM | $-129.77MM |
| Net Income(Loss)* | $-89.22MM | $-127.50MM | $-129.77MM |
| Stockholders Equity | $150.87MM | $240.97MM | $123.12MM |
| Assets | $272.15MM | $371.12MM | $228.79MM |
| Operating Cash Flow | $-61.36MM | $-110.82MM | $-135.32MM |
| Capital expenditure | $3.15MM | $3.83MM | $4.41MM |
| Investing Cash Flow | $-60.76MM | $-52.61MM | $109.37MM |
| Financing Cash Flow | $135.44MM | $208.76MM | $-0.34MM |
| Earnings Per Share** | $-1.36 | $-1.14 | $-1.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.